Tango Therapeutics, Inc. Contract with Customer, Liability, Noncurrent
Tango Therapeutics, Inc. (TNGX) had Contract with Customer, Liability, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-03-05
- 2025-12-31: Contract with Customer, Liability, Noncurrent $0.00.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $0.00.
- 2025-06-30: Contract with Customer, Liability, Noncurrent $30.44M.
- 2025-03-31: Contract with Customer, Liability, Noncurrent $37.51M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 |
| 2025-06-30 | $30.44M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $37.51M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $44.77M 10-K · filed 2026-03-05 |
| 2024-09-30 | $50.90M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $54.44M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $62.81M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $66.68M 10-K · filed 2025-02-27 |
| 2023-09-30 | $70.71M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $74.67M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $84.10M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $92.09M 10-K · filed 2024-03-18 |
| 2022-09-30 | $99.81M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $105.01M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $111.96M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $114.72M 10-K · filed 2023-03-27 |
| 2021-09-30 | $116.65M 10-Q · filed 2021-11-09 |
| 2020-12-31 | $120.81M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |